Lexicon Pharmaceuticals (Lexicon), a U.S. biopharmaceutical company, announced recently in The Woodlands, Texas, that it has entered into an exclusive licensing agreement with Danish pharmaceutical giant Novo Nordisk. Under the agreement, Novo Nordisk gains global exclusive rights to develop, manufacture, and commercialize LX9851, a novel oral non-incretin candidate targeting obesity and related metabolic disorders. Lexicon … Novo Nordisk Acquires Lexicon’s LX9851 for $1B to Expand Weight Loss Drug Portfolio Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.